The authors present their experience about 'timostimolina' (TP-1 Serono) therapy in patients radically resected between 1986-1988, for stage I non small cell lung cancer, particularly regarding the incidence of post-surgical infections and the 'disease free' period. Subjects were divided into two same groups of 20 patients each, as follow: a. TP-1 group, undergoing post-operatively to 'timostimolina' administration at the dose of 1 mg/kg by day alternatively, for 60 days; b. 'none' group, not treated. There was no infection in the 'thymostimulin group' and 17 patients are alive after 24 months of follow-up, while 2 of them present local recurrence. In the 'none group' 2 pulmonary infections occurred after surgery, 14 patients are alive, 2 of whom with recurrence, 1 regional and 1 metastatic. We confirm the thymostimulin efficacy in preventing postoperative infections. It also seems to be some positive influence on survival. These data have to be confirmed by an increased number of patients and by a longer follow-up.
|Translated title of the contribution||A pilot study about efficacy of immunostimulating therapy in patients radically operated for non small cell lung cancer (stage I). Early results|
|Number of pages||3|
|Publication status||Published - 1992|
ASJC Scopus subject areas